Goldman Sachs
HOWL icon

Goldman Sachs’s Werewolf Therapeutics HOWL Stock Holding History

Goldman Sachs’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.9K Buy
38,266
+4,193
+12% +$2.87K ﹤0.01% 6332
2025
Q4 		$21.6K Sell
34,073
-26,268
-44% -$31.9K ﹤0.01% 6339
2025
Q3 		$119K Sell
60,341
-167,101
-73% -$229K ﹤0.01% 6056
2025
Q2 		$248K Buy
227,442
+115,457
+103% +$119K ﹤0.01% 5550
2025
Q1 		$109K Sell
111,985
-29,845
-21% -$39.1K ﹤0.01% 5770
2024
Q4 		$210K Buy
141,830
+26,689
+23% +$54.4K ﹤0.01% 5628
2024
Q3 		$244K Buy
115,141
+63,052
+121% +$143K ﹤0.01% 5384
2024
Q2 		$127K Sell
52,089
-120,705
-70% -$580K ﹤0.01% 5369
2024
Q1 		$1.12M Buy
+172,794
New +$1.01M ﹤0.01% 4269
2022
Q3 		– Sell
-10,983
Closed -$45K – 6391
2022
Q2 		$45K Sell
10,983
-672
-6% -$3.07K ﹤0.01% 6049
2022
Q1 		$51K Buy
11,655
+1,575
+16% +$11K ﹤0.01% 6268
2021
Q4 		$120K Buy
+10,080
New +$152K ﹤0.01% 6086
2021
Q3 		– Sell
-37,435
Closed -$653K – 6340
2021
Q2 		$653K Buy
+37,435
New +$513K ﹤0.01% 5053

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs's HOWL Position: Q1 2026 in Review

Goldman Sachs increased its Werewolf Therapeutics (HOWL) stake by 12% in Q1 2026, buying an estimated $2.87K and bringing the position to 38,266 shares worth $31.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6332.

Goldman Sachs first reported a position in HOWL in Q2 2021 and has held it in 13 quarters since. The position peaked at $1.12M in Q1 2024. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Goldman Sachs held 38,266 shares of Werewolf Therapeutics worth $31.9K as of Q1 2026.
  • Goldman Sachs bought 4,193 Werewolf Therapeutics shares in Q1 2026, an estimated $2.87K.
  • Werewolf Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6332 holding.
  • Goldman Sachs first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 13 quarters since.
  • Goldman Sachs's Werewolf Therapeutics position peaked at $1.12M in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.